TD Private Client Wealth LLC Acquires 29,754 Shares of Pfizer Inc. (NYSE:PFE)

TD Private Client Wealth LLC raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 30.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 127,653 shares of the biopharmaceutical company's stock after buying an additional 29,754 shares during the quarter. TD Private Client Wealth LLC's holdings in Pfizer were worth $3,235,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the fourth quarter worth $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the fourth quarter worth $30,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. The Goldman Sachs Group boosted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Morgan Stanley boosted their price objective on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Citigroup boosted their target price on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.37 on Tuesday, hitting $25.61. The company had a trading volume of 51,253,171 shares, compared to its average volume of 46,119,828. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The stock has a market cap of $145.60 billion, a price-to-earnings ratio of 18.56, a P/E/G ratio of 0.92 and a beta of 0.58. The stock has a 50 day moving average price of $23.76 and a 200 day moving average price of $24.81. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the company earned $0.82 earnings per share. The company's quarterly revenue was down 7.8% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.72%. Pfizer's payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.